Process for producing N-biphenylmethylthiadiazoline derivative o

Details Process for producing N-biphenylmethylthiadiazoline derivative o Process for producing N-biphenylmethylthiadiazoline derivative o

1997-03-20

1999-10-12

Richter, Johann

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

548139, C07D28512

Patent

active

059657383

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The present invention relates to a process for producing an N-biphenylmethylthiadiazoline derivative or salt thereof which is useful as a therapeutic agent for circulatory diseases such as hypertension, heart diseases or cerebral apoplexy; and to an intermediate for producing the derivative or salt.


BACKGROUND ART

Angiotensin II is an active center of the renin-angiotensin system, and has powerful vasopressor action and stimulating action for the synthesis and secretion of aldosterone in the adrenal cortex. It is also known to be a substance causing hypertension. Its action is considered to be caused through a specific receptor on various target organs such as adrenal cortex, kidneys, arterioles and the peripheries of sympathetic nerves.
Known conventional examples of substances which show antihypertensive effects by pharmacological inhibition of the renin-angiotensin system include angiotensin-converting enzyme inhibitors such as captopril and enarapril, angiotensin II antagonists and renin inhibitors. As angiotensin II antagonist out of these, saralasin ([Sar1, Ala8] AGII), which is an angiotensin II type peptide, and nonpeptide derivatives such as imidazole derivatives (Japanese Patent Laid-Open Nos. SHO 56-7103 and SHO56-71074, and Japanese Language Laid-Open Publication No. HEI 3-501020) and pyrazole derivatives (Japanese Patent Laid-Open No. HEI 3-218371) are already known.
The peptide derivatives, however, have difficulty in clinical applications because of their short in vivo half-life, lack of effectiveness upon oral administration and significant agonistic activities. Among the nonpeptide derivatives, few drugs have been used clinically.
With a view toward providing a clinically excellent drug under such circumstances, the present inventors have carried out an extensive investigation. As a result, finding that an N-biphenylmethylthiadiazoline derivative represented by the below-described formula (7) or salt thereof has an excellent angiotensin II antagonistic action and are useful as therapeutics for circulatory diseases such as hypertension, heart diseases and cerebral apoplexy, the present inventors have already filed international patent application thereon (WO94/04516).
In that international application, an N-biphenylmethylthiadiazoline derivative (7) is prepared in accordance with the process as shown by the following reaction scheme.
The above process is however accompanied with the drawback that it includes a step of introducing a tetrazole group into a biphenylnitrile derivative in a manner known to date (Japanese Patent Laid-Open No. SHO 63-23868) so that a harmful trialkyltin compound should be used as a reagent for tetrazole introduction. The above process is therefore not fully satisfactory from the industrial viewpoint.
An object of the present invention is therefore to provide an industrially useful process for producing an N-biphenylmethylthiadiazoline derivative (7) or salt thereof which is an angiotensin antagonist, and also an intermediate for producing the same.


DISCLOSURE OF THE INVENTION

With the forgoing in view, the present inventors have carried out an extensive investigation on the process for producing an N-biphenylmethylthiadiazoline derivative (7) or salt thereof. As a result, it has been found that according to the production process through the novel compound (3a) or (3b), which will be described later, an N-biphenylmethylthiadiazoline derivative (7) or salt thereof can be prepared advantageously from the industrial viewpoint, leading to the completion of the invention.
A process for producing an N-biphenylmethylthiadiazoline derivative (7) or salt thereof according to the present invention is represented by the following reaction scheme: ##STR2## wherein R.sup.1 represents a lower alkyl group, R.sup.2 represents a hydrogen atom or an acyl group, R.sup.2a represents an acyl group, X.sup.1 represents a halogen atom, X.sup.2 represents a halogen atom or a group --SO.sub.3 R.sup.3 in which R.sup.3 represents an alkyl or aryl group, Z represents a

REFERENCES:
patent: 5389660 (1995-02-01), Greenlee et al.
patent: 5434167 (1995-07-01), Ferrari et al.
patent: 5654322 (1997-08-01), Hirata et al.
David M. Rackham, et al., Organic Magnetic Resonance, vol. 14, No. 6, pp. 515-516, "C NMR Spectra of 1,3,4--Thiadiazole/Thiadiazoline Isomeric Pairs", 1980.
John W. Ellingboe, et al., Journal of Medicinal Chemistry, American Chemical Society, vol. 37, No. 4, pp. 542-550, "Pyrido [2,3,--D]Pyrimidine Angiotensin II Antagonists", 1984.

Affiliated with

Also associated with

Rating

Process for producing N-biphenylmethylthiadiazoline derivative o does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for producing N-biphenylmethylthiadiazoline derivative o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for producing N-biphenylmethylthiadiazoline derivative o will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-654149